BiotechTube

BXCL501 + BXCL501 + Placebo film

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Agitation

Conditions

Agitation, Dementia

Trial Timeline

Feb 8, 2022 → Apr 1, 2022

NCT ID
NCT05276830

About BXCL501 + BXCL501 + Placebo film

BXCL501 + BXCL501 + Placebo film is a phase 2 stage product being developed by BioXcel Therapeutics for Agitation. The current trial status is terminated. This product is registered under clinical trial identifier NCT05276830. Target conditions include Agitation, Dementia.

What happened to similar drugs?

2 of 14 similar drugs in Agitation were approved

Approved (2) Terminated (2) Active (10)
✅Quetiapine + Haloperidol + Lorazepam + CogentinAstraZenecaApproved
🔄Brexpiprazole, OPC-34712LundbeckPhase 3
🔄Brexpiprazole, OPC-34712 + Placebo Oral TabletLundbeckPhase 3
🔄BrexpiprazoleLundbeckPhase 3
🔄AXS-05 (dextromethorphan-bupropion) + PlaceboAxsome TherapeuticsPhase 3
❌AXS-05 (dextromethorphan-bupropion)Axsome TherapeuticsPhase 3
🔄AXS-05 + PlaceboAxsome TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05276830Phase 2Terminated

Competing Products

20 competing products in Agitation

See all competitors
ProductCompanyStageHype Score
ONO-2020 + PlaceboOno PharmaceuticalPhase 2
42
Quetiapine + Haloperidol + Lorazepam + CogentinAstraZenecaApproved
43
Brexpiprazole, OPC-34712LundbeckPhase 3
37
Brexpiprazole, OPC-34712 + Placebo Oral TabletLundbeckPhase 3
37
BrexpiprazoleLundbeckPhase 3
37
AXS-05 (dextromethorphan-bupropion) + PlaceboAxsome TherapeuticsPhase 3
37
AXS-05 + Bupropion + PlaceboAxsome TherapeuticsPhase 2/3
35
AXS-05 (dextromethorphan-bupropion)Axsome TherapeuticsPhase 3
29
AXS-05 + PlaceboAxsome TherapeuticsPhase 3
37
AXS-05 + PlaceboAxsome TherapeuticsPhase 3
37
Pimavanserin 34 mg + Pimavanserin 20 mgAcadia PharmaceuticalsPhase 2
24
PimavanserinAcadia PharmaceuticalsPhase 2
32
Sublingual film containing Dexmedetomidine (BXCL501) + Placebo FilmBioXcel TherapeuticsPhase 3
30
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
22
Sublingual film containing BXCL501 (Dexmedetomidine) + Placebo filmBioXcel TherapeuticsPhase 1
19
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
30
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
30
Sublingual film containing dexmedetomidine (BXCL501) + Placebo FilmBioXcel TherapeuticsPhase 3
30
BXCL501 + Placebo filmBioXcel TherapeuticsPhase 2
17
Sublingual film containing Dexmedetomidine + Sublingual Placebo FilmBioXcel TherapeuticsPhase 1/2
22